# A Study to Assess Safety, Tolerability and PK of AZD2171 and Chemotherapy on Patients With Solid Tumors

> **NCT00502567** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 104 (actual)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** AZD2171
- **DRUG:** FOLFOX
- **DRUG:** Pemetrexed
- **DRUG:** Irinotecan (administered with & without Cetuximab)
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT00502567
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-01
- **Primary completion:** 2007-11
- **Final completion:** 2011-06
- **Target enrollment:** 104 (ACTUAL)
- **Last updated:** 2011-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00502567

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00502567, "A Study to Assess Safety, Tolerability and PK of AZD2171 and Chemotherapy on Patients With Solid Tumors". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00502567. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*